Real-world experience of spesolimab for generalized pustular psoriasis flares in adult patients: A multicenter retrospective study

Spesolimab is a novel interleukin-36 receptor inhibitor recently approved for treatment of generalized pustular psoriasis (GPP). While clinical trials have evaluated its efficacy and safety for this indication, real-world evidence (RWE) is sparse. Herein, we report real-world use of spesolimab in the clinical setting.

斯派索利单抗是一种新型的白介素-36受体抑制剂，近期已获批准用于治疗泛发性脓疱型银屑病（GPP）。尽管临床试验已评估了其在该适应症下的疗效与安全性，但真实世界证据（RWE）仍然有限。在此，我们报道了斯派索利单抗在临床环境中的真实世界应用情况。